cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)
cell (2)

Cell-Based Cancer Cure
for Solid Tumors and Hematological Cancers

Cellicure provides innovative, cell-based immunotherapy technologies, customized treatment regimens and real world solutions to solve the current unmet therapeutic needs created by cancer, infectious diseases, and chronic inflammatory diseases.

nCAR-TTM Platforms

Genomic miRNA “Trogocytosis” screening and RNAseq and ATACseq analysis have demonstrated that the miR200c-Zeb1-EpCAM axis is associated with prolonged in vivo T cell presistence. miR200c suppresses the expression of Zeb1, a zinc finger and homeodomain transcription factor that binds, caps, and suppresses the EpCAM gene causing a decrease in EpCAM transcription.

Suppression of Zeb1 results in an increase in EpCAM transcription leading to the EpCAM intercellular domain recruitment of FHL2 and β-catenin. The recruitment then forms a complex that translocates to the nucleus with Lef1 and TCF1 triggering target gene expression. This process mediates cell survival leading to long-term cellular proliferation in vivo as well as improved T cell immunotherapy in liquid and solid tumors.

Share this page

Facebook
Twitter
LinkedIn
Email